Beta-adrenergic blockade (propranolol) in burn care

Overview¶

Severe burns produce the most extreme and sustained hypermetabolic state of any survivable injury. Wilmore and colleagues established in 1974 that the metabolic rate after thermal injury is positively related to the rate of urinary catecholamine excretion, and that burned patients are internally warm rather than externally cold, with catecholamines mediating their increased heat production ^[1]. That insight reframed post-burn hypermetabolism as a catecholamine-driven phenomenon and made adrenergic blockade a rational target. Propranolol, a nonselective beta-1/beta-2 antagonist, attenuates hypermetabolism and catabolism in severely burned patients ^[5].

The modern clinical case rests on a 2001 New England Journal of Medicine randomized trial in burned children: propranolol given during hospitalization, at doses adjusted to lower resting heart rate by 20% from baseline, attenuated hypermetabolism and reversed muscle-protein catabolism ^[2]. Among the proposed pharmacologic modulators of the post-burn hypermetabolic response, propranolol has been characterized as probably the most efficacious anticatabolic therapy in the treatment of burns ^[34]. The bulk of trial evidence is pediatric; systematic reviews note that most studies have been conducted in pediatric burn patients ^[6].

Adoption has outpaced the adult evidence. A survey of burn centers found that 60.5% use propranolol, that the majority (60.8%) initiate it in patients with burns over 20% TBSA, and that practice patterns vary widely in dose, route, and duration ^[26]. This page covers the physiologic rationale, mechanism, indications, dosing, the outcome evidence across cardiac, metabolic, wound-healing, and body-composition endpoints, and the safety profile.

The catecholamine-driven hypermetabolic response¶

Hypermetabolism, increased heart rate, and lipolysis are responses to the high catecholamine levels associated with burn injury ^[12]. The hypercatabolic response in severely burned children is associated with increased production of catecholamines and corticosteroids, decreased testosterone formation, and reduced strength alongside growth arrest for up to two years after injury ^[18]. The catecholamine-mediated hypermetabolic response causes increased energy expenditure and muscle-protein catabolism ^[2].

Several downstream mechanisms have been mapped. Increased triglyceride-fatty-acid substrate cycling contributes to the increased thermogenesis and energy expenditure following severe burns, and this increased cycling is driven by beta-adrenergic stimulation ^[42]. Lipolysis characteristic of severely burned patients is caused by stimulation of beta-2 adrenergic receptors for catecholamines ^[41]. Accelerated lipolysis in severely burned children plays an important role in the accumulation of hepatic triglycerides, and beta-adrenergic blockade can reduce delivery of fatty acids to the liver and the hepatic congestion commonly found in these children by inhibiting lipolysis and reducing hepatic blood flow ^[38]. Catecholamine release also drives a hepatic endoplasmic-reticulum stress response that activates c-Jun N-terminal kinase and impairs insulin-receptor signaling ^[43].

Mechanism of action¶

Propranolol is a competitive blocker of catecholamine binding to beta-adrenergic receptors ^[44]. As a nonselective beta-1/beta-2 antagonist it diminishes the catecholamine-mediated elevations in heart rate and myocardial contractility that characterize post-burn hypermetabolism ^[37]. Its anticatabolic effect appears to occur through increased protein synthesis in the face of persistent protein breakdown together with reduced peripheral lipolysis ^[45].

The drug acts on multiple tissues. By leaving alpha-adrenergic receptors unopposed, propranolol exerts an indirect vasoconstrictive effect that increases vascular resistance and diminishes peripheral blood flow following burn injury ^[14]. A metabolomic analysis of adipose tissue from a randomized trial found that propranolol alters essential pathways involved in energy and nucleotide metabolism and catecholamine degradation, with these effects mediated by decreased activation of hormone-sensitive lipase and significantly reduced endoplasmic-reticulum stress ^[25]. At the receptor level, burn trauma alters the expression, trafficking, and degradation of beta-adrenergic receptors in dermal fibroblasts, and propranolol increases their cell-surface expression while abrogating lysosomal receptor degradation, a candidate mechanism for its effect on hypertrophic scarring ^[35].

Indications and patient selection¶

Propranolol is used to attenuate the hypermetabolic response related to thermal injury ^[26]. Survey data describe the operative selection threshold in current practice: the majority of centers (60.8%) initiate propranolol in patients with burns over 20% TBSA, and use in both adult and pediatric patients was reported in 82% of centers ^[26]. Trials have enrolled patients across a range of burn sizes, from 20-40% TBSA in adult wound-healing studies to over 30% TBSA in the long-term pediatric trials ^[3,16].

The original case-series description of beta-blockade in burns noted possible contraindications including obstructive lung disease and shock ^[39]. Selection in practice remains heterogeneous; the survey authors concluded that wide variation in practice patterns highlights the need for further study of patient outcomes, duration of therapy, and dosing to drive consensus guidelines ^[26].

Dosing and administration¶

Across trials, propranolol is titrated to a physiologic target rather than a fixed dose: the dose is adjusted to decrease resting heart rate by approximately 15-20% from each patient's baseline value ^[2]. In the dose-finding pediatric study, propranolol given initially at 1 mg/kg/day decreased heart rate by 15% but was increased to 4 mg/kg/day within the first 10 days to sustain treatment benefits, with effective plasma concentrations achieved in 30 minutes and a half-life of about 4 hours ^[4]. The long-term pediatric trial used 4 mg/kg/day ^[3].

Route and timing vary. In wound-healing trials, propranolol was administered within 48 hours of burns and continued through hospital discharge ^[14]. The drug has been given orally, by feeding tube, by nasogastric tube, and intravenously; one pediatric study found that both oral and intravenous routes were safe and effective, with intravenous dosing lowering heart rate more per mg/kg ^[13]. Reported doses differ by age and population: a large pediatric outpatient cohort recorded mean doses of 5.2 mg/kg/day in children aged 0-3 years, 4.2 mg/kg/day in those 4-10 years, and 2.9 mg/kg/day in those 11-18 years, with the dose decreasing as time post-burn increased ^[28]. In that cohort propranolol was stopped abruptly with no rebound hypertension ^[28]. Adult dosing runs lower; a retrospective adult analysis reported an average maximum dose of 0.61 mg/kg/day and concluded that adults do not tolerate the higher doses reported in pediatric populations ^[27].

Outcomes¶

Cardiac work and the hypermetabolic response¶

The most consistent and best-replicated effect is reduction of cardiac work. In burned children, propranolol significantly reduced percent-predicted heart rate, mean arterial pressure, cardiac index, cardiac work, and rate-pressure product ^[22]. In the dose-finding study, 4 mg/kg/day decreased cardiac output, rate-pressure product, and cardiac work without deleterious effects on mean arterial pressure, and sustained heart rate 15% below admission levels ^[4]. An early hemodynamic study in patients with large burns reported heart rate, left-ventricular work, and rate-pressure product reduced by 20%, 22%, and 36% respectively, without adversely reducing cardiac output or resting energy expenditure ^[12].

The metabolic effect parallels the cardiac one. In the 2001 NEJM trial, beta-blockade decreased both heart rate and resting energy expenditure relative to baseline and to controls ^[2]. A systematic review found that propranolol at doses adjusted to reduce heart rate by 20% of baseline (4-6 mg/kg/day orally) reduces supraphysiologic thermogenesis, cardiac work, resting energy expenditure, and peripheral lipolysis ^[6]. An adult randomized trial reported significantly lower resting energy expenditure on days 7 and 14 in the propranolol group, and limited the increase in liver size seen in controls ^[24].

Wound healing and grafting¶

Several randomized trials report faster wound healing with propranolol. In severely burned adults, propranolol diminished blood loss during skin grafting and was associated with a shorter average interval between grafting procedures (10 days versus 17 days), indicating faster donor-site healing ^[14]. A randomized trial in hospitalized burn patients found that propranolol shortened the time to acceptable healing in superficial burns (16.1 versus 21.5 days) and the time to graft-readiness in deep burns (28.2 versus 33.5 days), and reduced the surface area requiring grafting ^[15]. An adult trial in patients with 20-40% TBSA burns similarly reported shorter healing times for superficial burns (13.2 versus 20.3 days) and shorter time to graft-readiness for deep burns (23.9 versus 33.6 days) ^[16]. The adult RCT by Lam and colleagues found significantly shorter complete-healing times for partial-thickness burns and donor sites ^[24].

Body composition and muscle¶

The anticatabolic signal is robust and well replicated in children. In the 2001 trial, net muscle-protein balance increased by 82% over baseline in the propranolol group while it fell by 27% in controls, and fat-free mass was preserved in the propranolol group but fell by a mean 9% in controls ^[2]. A four-arm trial comparing untreated control, growth hormone, propranolol, and combination therapy in children with over 40% TBSA burns found that net muscle-protein balance improved during propranolol and combination treatment with no significant benefit of growth hormone alone and no additive effect of combination, characterizing propranolol as a strongly anabolic drug during the early hypercatabolic period ^[17]. Long-term propranolol for 12 months after injury significantly reduced percent-predicted heart rate and resting energy expenditure, decreased central mass and central fat accumulation, prevented bone loss, and improved lean-body-mass accretion ^[3].

Combination with the testosterone analog oxandrolone has been studied for longer-term recovery. Combined oxandrolone and propranolol for one year shortened the period of growth arrest by 84 days and increased growth rate by 1.7 cm/year versus control ^[18], accelerated muscle recovery when added to resistance exercise training ^[19], and was associated with reduced scar cellularity, attenuated scar severity, increased pliability, and improved patient-reported general and emotional health ^[21]. Propranolol does not blunt the benefits of exercise: in a trial of exercise training, the percent change in peak oxygen consumption was significantly greater in the propranolol group than in controls, and exercise-induced gains in muscle mass, strength, and peak oxygen consumption were not impaired by the drug ^[20].

Pooled estimates from systematic reviews¶

Meta-analyses converge on the physiologic and metabolic benefits while finding no survival signal. A 2016 meta-analysis of 9 randomized and 1 nonrandomized trial found that propranolol significantly decreased resting energy expenditure and trunk fat and improved peripheral lean mass and insulin resistance, with adverse-event rates no different from controls ^[7]. A 2020 meta-analysis of 12 RCTs (1887 patients) found decreased heart rate, rate-pressure product, and mean arterial pressure, shorter adult length of stay, and shorter graft-preparation time, without increased mortality, sepsis, or PTSD ^[8]. A 2025 updated meta-analysis of 14 RCTs (2114 patients) reported decreased heart rate, mean arterial pressure, rate-pressure product, resting energy expenditure, and wound-healing time, with no reduction in mortality, sepsis, or hospital length of stay ^[9]. A 2017 systematic review of 10 studies (1236 participants) found no differences in mortality or sepsis but lower blood-transfusion requirements and heart rate in propranolol-treated adults ^[11]. An adult observational study reported a lower mortality rate among patients on premorbid beta-blockers than among controls (5% versus 13%), and in multivariate analysis premorbid beta-blocker use was associated with a significant decrease in fatal outcome and healing time, leading the authors to conclude that beta-blockers have the potential to improve adult burn outcomes ^[23].

Safety and complications¶

The hemodynamic adverse effects are predictable extensions of beta-blockade. A retrospective adult dosing analysis found that 72% of patients experienced at least one episode of hypotension and 15% experienced bradycardia, with doses most frequently held for low blood pressure (32% of patients) ^[27]; the authors concluded that burn-care providers must recognize the potential iatrogenic hemodynamic effects of this intervention ^[27]. The adult RCT by Lam and colleagues recorded hypotension in 11.9%, bradycardia in 1.6%, and hypoglycemia in 17.7% of patients ^[24]. In pediatric experience the safety profile has been more favorable: a large outpatient cohort of 104 children treated for one to two years reported no adverse effects ^[28], and the long-term randomized trial reported very few adverse effects at 4 mg/kg/day ^[3].

Concerns about oxygen delivery and infection have been examined directly. Although beta-blockers decrease cardiac output and could theoretically reduce oxygen delivery and increase mortality ^[23], a pediatric randomized trial found that propranolol reduced cardiac index without reducing peripheral oxygen delivery and without higher rates of lactic acidosis or organ dysfunction ^[22]. On the immune question, the randomized trial by Jeschke and colleagues found that propranolol did not increase the incidence of infection (21% versus 30% in controls) or sepsis (7% versus 10%) and significantly decreased serum tumor necrosis factor and interleukin-1-beta ^[5]. A serious but rare complication has been described: a case report of two children who developed fatal non-occlusive mesenteric ischemia, in whom propranolol was continued through preceding septic-shock episodes, raising the concern that unopposed alpha-adrenergic activity during hypotension could cause severe splanchnic vasoconstriction ^[29].

Special considerations¶

The pediatric-versus-adult divide is the dominant theme. Most studies have been conducted in pediatric burn patients ^[6], and adults do not tolerate the higher per-kilogram doses reported in pediatric populations ^[27]. Pediatric burn patients often have hypertension and tachycardia for several years post-injury, which underlies the rationale for prolonged outpatient therapy ^[28].

Propranolol has been studied for psychiatric and thermoregulatory endpoints with largely negative results. In burned service members, the prevalence of PTSD was 32.3% with propranolol versus 26.5% without (not significant), and the data suggest propranolol does not decrease PTSD development ^[30]. In children, the prevalence of PTSD, anxiety, and depression was similar between those who received propranolol acutely and those who did not ^[31]. A genotype-based pilot RCT found that propranolol is unlikely to be a useful analgesic in the first weeks after burn injury, with worse pain scores on study days 5 to 19 in the propranolol arm ^[32]. On thermoregulation, resting beta-adrenergic blockade did not affect the internal body temperature of burned children exercising at similar relative intensities in the heat ^[40].

Controversies and Evidence Gaps¶

The central tension is between robust physiologic benefit and absent hard-outcome benefit. Pooled randomized data consistently show reduced heart rate, cardiac work, and resting energy expenditure, and in some analyses faster wound healing and shorter adult length of stay ^[8,9]. They do not show a mortality or sepsis benefit: a 2025 meta-analysis found no reduction in mortality, sepsis, or length of stay ^[9], and a 2021 systematic review graded the evidence as very low certainty, concluding that no sufficient evidence was found to support or refute an advantage for beta-blocker use in children or adults after burns ^[10]. A 2017 review likewise judged the evidence too limited to conclude that propranolol reduces length of stay ^[11].

The evidence base is unbalanced toward children. A 2015 review found that beta-blockers reduce the hypermetabolic state in pediatric patients but that there is insufficient evidence on mortality or length of stay ^[33], and systematic reviewers have repeatedly called for further adult trials with a broader range of outcome measures ^[7]. Open questions named in the literature include the optimal beta-blocker agent, indications for initiation, and duration of treatment, which a 2021 review identified as needing additional study to formulate practice guidelines ^[10]. There is also a mechanistic counter-signal: because synthetic beta-adrenergic agonists promote muscle growth, blunting muscle beta-adrenergic signaling with propranolol would be expected to impair muscle protein homeostasis, a tension that has prompted proposals to refine beta-blocker therapy so it preserves muscle recovery while still attenuating whole-body hypermetabolism ^[36]. Finally, surveyed clinicians themselves are uncertain: propranolol was felt to improve outcomes in 56% of survey responses while 39% were unsure ^[26].

References¶

[1] Wilmore DW, Long JM, Mason AD, Skreen RW, Pruitt BA. "Catecholamines: mediator of the hypermetabolic response to thermal injury." Annals of surgery 1974. PMID: 4412350 ↩

[2] Herndon DN, Hart DW, Wolf SE, Chinkes DL, Wolfe RR. "Reversal of catabolism by beta-blockade after severe burns." The New England journal of medicine 2001. PMID: 11680441 ↩

[3] Herndon DN, Rodriguez NA, Diaz EC, Hegde S, Jennings K, et al. "Long-term propranolol use in severely burned pediatric patients: a randomized controlled study." Annals of surgery 2012. PMID: 22895351 ↩

[4] Williams FN, Herndon DN, Kulp GA, Jeschke MG. "Propranolol decreases cardiac work in a dose-dependent manner in severely burned children." Surgery 2011. PMID: 20598332 ↩

[5] Jeschke MG, Norbury WB, Finnerty CC, Branski LK, Herndon DN. "Propranolol does not increase inflammation, sepsis, or infectious episodes in severely burned children." The Journal of trauma 2007. PMID: 17414346 ↩

[6] Núñez-Villaveirán T, Sánchez M, Millán P, García-de-Lorenzo A. "Systematic review of the effect of propanolol on hypermetabolism in burn injuries." Medicina intensiva 2015. PMID: 25305241 ↩

[7] Flores O, Stockton K, Roberts JA, Muller MJ, Paratz JD. "The efficacy and safety of adrenergic blockade after burn injury: A systematic review and meta-analysis." The journal of trauma and acute care surgery 2016. PMID: 26517779 ↩

[8] Ma J, Hu D, Feng Z, Tang J, Guo L, et al. "The effectiveness and safety of beta antagonist in burned patients: A systematic review and meta-analysis." International wound journal 2020. PMID: 32820612 ↩

[9] Bhatti A, Shah S, Shahzaib M, Nadeem MA, Shaikh A, et al. "The Effectiveness and Safety of Beta Antagonists in Patients With Burns: An Updated Meta-Analysis." The American surgeon 2025. PMID: 39792849 ↩

[10] Hassoun-Kheir N, Henig O, Avni T, Leibovici L, Paul M. "The Effect of β-Blockers for Burn Patients on Clinical Outcomes: Systematic Review and Meta-Analysis." Journal of intensive care medicine 2021. PMID: 32686565 ↩

[11] Manzano-Nunez R, García-Perdomo HA, Ferrada P, Ordoñez Delgado CA, Gomez DA, Foianini JE. "Safety and effectiveness of propranolol in severely burned patients: systematic review and meta-analysis." World journal of emergency surgery : WJES 2017. PMID: 28265298 ↩

[12] Herndon DN, Barrow RE, Rutan TC, Minifee P, Jahoor F, Wolfe RR. "Effect of propranolol administration on hemodynamic and metabolic responses of burned pediatric patients." Annals of surgery 1988. PMID: 3052328 ↩

[13] Baron PW, Barrow RE, Pierre EJ, Herndon DN. "Prolonged use of propranolol safely decreases cardiac work in burned children." The Journal of burn care & rehabilitation 1997. PMID: 9169945 ↩

[14] Ali A, Herndon DN, Mamachen A, Hasan S, Andersen CR, et al. "Propranolol attenuates hemorrhage and accelerates wound healing in severely burned adults." Critical care (London, England) 2015. PMID: 25936635 ↩

[15] Mohammadi AA, Bakhshaeekia A, Alibeigi P, Hasheminasab MJ, Tolide-ei HR, et al. "Efficacy of propranolol in wound healing for hospitalized burn patients." Journal of burn care & research : official publication of the American Burn Association 2009. PMID: 19826272 ↩

[16] Cheema SA, Ahmed UT, Nasir H, Dogar SR, Mustafa Z. "Effects of Propranolol in Accelerating Wound Healing and Attenuation of Hypermetabolism in Adult Burn Patients." Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 2020. PMID: 31931932 ↩

[17] Hart DW, Wolf SE, Chinkes DL, Lal SO, Ramzy PI, Herndon DN. "Beta-blockade and growth hormone after burn." Annals of surgery 2002. PMID: 12368673 ↩

[18] Herndon DN, Voigt CD, Capek KD, Wurzer P, Guillory A, et al. "Reversal of Growth Arrest With the Combined Administration of Oxandrolone and Propranolol in Severely Burned Children." Annals of surgery 2016. PMID: 27433905 ↩

[19] Chao T, Porter C, Herndon DN, Siopi A, Ideker H, et al. "Propranolol and Oxandrolone Therapy Accelerated Muscle Recovery in Burned Children." Medicine and science in sports and exercise 2018. PMID: 29040226 ↩

[20] Porro LJ, Al-Mousawi AM, Williams F, Herndon DN, Mlcak RP, Suman OE. "Effects of propranolol and exercise training in children with severe burns." The Journal of pediatrics 2013. PMID: 23084706 ↩

[21] Herndon D, Capek KD, Ross E, Jay JW, Prasai A, et al. "Reduced Postburn Hypertrophic Scarring and Improved Physical Recovery With Yearlong Administration of Oxandrolone and Propranolol." Annals of surgery 2018. PMID: 30048322 ↩

[22] Wurzer P, Branski LK, Clayton RP, Hundeshagen G, Forbes AA, et al. "Propranolol Reduces Cardiac Index But does not Adversely Affect Peripheral Perfusion in Severely Burned Children." Shock (Augusta, Ga.) 2016. PMID: 27380530 ↩

[23] Arbabi S, Ahrns KS, Wahl WL, Hemmila MR, Wang SC, et al. "Beta-blocker use is associated with improved outcomes in adult burn patients." The Journal of trauma 2004. PMID: 14960966 ↩

[24] Lam NN, Khanh PQ, An NH. "The use of propranolol in adult burn patients: Safety and outcome influence." Burns : journal of the International Society for Burn Injuries 2022. PMID: 34895792 ↩

[25] Rehou S, de Brito Monteiro L, Auger C, Knuth CM, Abdullahi A, et al. "Propranolol Normalizes Metabolomic Signatures Thereby Improving Outcomes After Burn." Annals of surgery 2023. PMID: 37389480 ↩

[26] LeCompte MT, Rae L, Kahn SA. "A survey of the use of propranolol in burn centers: Who, what, when, why." Burns : journal of the International Society for Burn Injuries 2017. PMID: 27575676 ↩

[27] Brown DA, Gibbons J, Honari S, Klein MB, Pham TN, Gibran NS. "Propranolol Dosing Practices in Adult Burn Patients: Implications for Safety and Efficacy." Journal of burn care & research : official publication of the American Burn Association 2016. PMID: 25882517 ↩

[28] Ojeda S, Blumenthal E, Stevens P, Andersen CR, Robles L, et al. "The Safety and Efficacy of Propranolol in Reducing the Hypermetabolic Response in the Pediatric Burn Population." Journal of burn care & research : official publication of the American Burn Association 2018. PMID: 29757441 ↩

[29] Martinez R, Rogers A, Numanoglu A, Rode H. "Fatal non-occlusive mesenteric ischemia and the use of propranolol in paediatric burns." Burns : journal of the International Society for Burn Injuries 2016. PMID: 26899618 ↩

[30] McGhee LL, Maani CV, Garza TH, Desocio PA, Gaylord KM, Black IH. "The effect of propranolol on posttraumatic stress disorder in burned service members." Journal of burn care & research : official publication of the American Burn Association 2009. PMID: 19060728 ↩

[31] Rosenberg L, Rosenberg M, Sharp S, Thomas CR, Humphries HF, et al. "Does Acute Propranolol Treatment Prevent Posttraumatic Stress Disorder, Anxiety, and Depression in Children with Burns?." Journal of child and adolescent psychopharmacology 2018. PMID: 29161523 ↩

[32] Orrey DC, Halawa OI, Bortsov AV, Shupp JW, Jones SW, et al. "Results of a pilot multicenter genotype-based randomized placebo-controlled trial of propranolol to reduce pain after major thermal burn injury." The Clinical journal of pain 2015. PMID: 25084070 ↩

[33] Shan Chew EC, Baier N, Lee JH. "Do β-Blockers Decrease the Hypermetabolic State in Critically Ill Children With Severe Burns?." Hospital pediatrics 2015. PMID: 26231635 ↩

[34] Gauglitz GG, Williams FN, Herndon DN, Jeschke MG. "Burns: where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogs?." Current opinion in clinical nutrition and metabolic care 2011. PMID: 21157309 ↩

[35] El Ayadi A, Prasai A, Wang Y, Herndon DN, Finnerty CC. "β-Adrenergic Receptor Trafficking, Degradation, and Cell Surface Expression Are Altered in Dermal Fibroblasts from Hypertrophic Scars." The Journal of investigative dermatology 2018. PMID: 29476776 ↩

[36] Blears E, Ross E, Ogunbileje JO, Porter C, Murton AJ. "The impact of catecholamines on skeletal muscle following massive burns: Friend or foe?." Burns : journal of the International Society for Burn Injuries 2021. PMID: 33568281 ↩

[37] Gore DC, Honeycutt D, Jahoor F, Barrow RE, Wolfe RR, Herndon DN. "Propranolol diminishes extremity blood flow in burned patients." Annals of surgery 1991. PMID: 2039287 ↩

[38] Barrow RE, Wolfe RR, Dasu MR, Barrow LN, Herndon DN. "The use of beta-adrenergic blockade in preventing trauma-induced hepatomegaly." Annals of surgery 2006. PMID: 16371745 ↩

[39] Szabó K. "Clinical experiences with beta adrenergic blocking therapy on burned patients." Scandinavian journal of plastic and reconstructive surgery 1979. PMID: 36657 ↩

[40] Rivas E, McEntire SJ, Herndon DN, Suman OE. "Resting β-Adrenergic Blockade Does Not Alter Exercise Thermoregulation in Children With Burn Injury: A Randomized Control Trial." Journal of burn care & research : official publication of the American Burn Association 2018. PMID: 28661984 ↩

[41] Herndon DN, Nguyen TT, Wolfe RR, Maggi SP, Biolo G, et al. "Lipolysis in burned patients is stimulated by the beta 2-receptor for catecholamines." Archives of surgery (Chicago, Ill. : 1960) 1994. PMID: 7986160 ↩

[42] Wolfe RR, Herndon DN, Jahoor F, Miyoshi H, Wolfe M. "Effect of severe burn injury on substrate cycling by glucose and fatty acids." The New England journal of medicine 1987. PMID: 3614284 ↩

[43] Brooks NC, Song J, Boehning D, Kraft R, Finnerty CC, et al. "Propranolol improves impaired hepatic phosphatidylinositol 3-kinase/akt signaling after burn injury." Molecular medicine (Cambridge, Mass.) 2012. PMID: 22396018 ↩

[44] Kobayashi M, Jeschke MG, Asai A, Kogiso M, Yoshida S, et al. "Propranolol as a modulator of M2b monocytes in severely burned patients." Journal of leukocyte biology 2011. PMID: 21330352 ↩

[45] Pereira CT, Jeschke MG, Herndon DN. "Beta-blockade in burns." Novartis Foundation symposium 2007. PMID: 17380798 ↩